672P Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab

Abstract

Cabozantinib is a tyrosine kinase inhibitor approved in Europe for use in adults with aRCC who have received prior VEGF-targeted therapy, or are treatment naive with intermediate or poor risk. We report interim data on the real-world use of cabozantinib in patients with aRCC who have received prior VEGF-targeted therapy and nivolumab.